CAMELIA – Chronic MyEloid LeukaemIA

The CAMELIA project (Chronic MyEloid LeukaemIA) is focused on monitoring of patients with chronic myeloid leukaemia (CML) in everyday clinical practice. Its aim is to monitor all CML patients in participating haemato-oncology centres, regardless of their treatment modalities.

The project was initiated at the Institute of Biostatistics and Analyses of the Masaryk University (IBA MU) and has continued at the Institute of Biostatistics and Analyses Ltd (IBA Ltd), a university company.

The structure of monitored data has been designed in a way which makes it possible to collect data on three levels:

1. Extended records – monitoring of principal clinical and laboratory data with particular focus on the type of treatment and results of cytogenetic and molecular-genetic examinations, aiming to evaluate the effectiveness of CML treatment.
2. Basic records – monitoring of basic epidemiological and clinical data in CML patients.
3. Specific topics – the system's flexibility and modularity allows the collection and analysis of specific data with the aim to verify scientific hypotheses (development of other malignant tumours in patients treated with tyrosin kinase inhibitors, patients not responding to treatment, tyrosin kinase inhibitors and pregnancy etc.).

Organization and cooperation

Since the very beginning in 2005, the CAMELIA project has been organized as an international project: haemato-oncology centres from the Czech Republic and Slovakia are involved. The project aims to coordinate the procedures in CML treatment, taking into account international guidelines as well as possibilities of participating centres. The CAMELIA project is open for further cooperation: its background and coordination are ready to be extended for other interested parties.

Involvement in international projects

The CAMELIA project is closely linked to international projects focused on the issues related to leukaemias; through the mediation of participating institutions, the project is part of the European LeukemiaNet and the EUTOS for CML project.

Other important information:

• Expert guarantor: prof. MUDr. Karel Indrák, DrSc. (Czech Society of Haematology), MUDr. Zuzana Sninská, Ph.D. (Slovak Society of Haematology and Transfusiology)
• Funding: Novartis Ltd.
• Partners: 11 haemato-oncology centres from the Czech Republic and Slovakia (the comprehensive list is available on the website of the CAMELIA project)
• Brief overview of results: you can find more detailed information on the website of the CAMELIA project

CAMELIA CZ as part of the CAMELIA project was finished in 2021, and CAMELIA SK was finished in 2023.